Dr. Reddy’s Laboratories (Hyderabad, Andhra Pradesh, India) has entered into a technology transfer, manufacturing, and marketing agreement with R-Pharm (Moscow), a Russian pharmaceutical company. The agreement is based on a profit-sharing model and will entail licensing of manufacturing know-how of products by Dr. Reddy’s, local manufacturing of products in Russia, codevelopment of high-technology products, and knowledge sharing between the two companies.
R-Pharm was founded in 2001 and is involved in research and development (R&D), manufacturing of active ingredients and finished drug products, promotion, and distribution of pharmaceuticals used in hospitals and specialty care. It employs approximately 400 people and has 15 affiliates in the Russian Federation.
“We are excited about the collaboration as it helps us to deepen our engagement with Russia, one of our key markets,” said Satish Reddy, managing director and COO of Dr. Reddy’s in a Dec. 21, 2010, press release. “The agreement allows us to bring innovative medicines to the Russian people with active collaboration of a local pharmaceutical company, R-Pharm. It will also allow Dr. Reddy’s to import and market R-Pharm products in India according to agreed terms. The collaboration demonstrates our commitment to play a leading role in supporting the Russian government’s policy of Pharma 2020.”
Pharma 2020 is a plan by the Russian government to develop R&D and manufacturing of drugs by Russia’s domestic pharmaceutical sector. The plan seeks to elevate the market share of domestically produced generic and innovator drugs through increased investments in technology as well as R&D.
Dr. Reddy’s signed the agreement with R-Pharm at the India–Russia Forum on Trade and Investment in New Delhi on Dec. 20, 2010. The forum coincided with the visit of Russian President Dmitriy Medvedev to India.